Strs Ohio Takes $86.20 Million Position in Merck & Co., Inc. $MRK

Key Points

• Strs Ohio has acquired a new position in Merck & Co., Inc., purchasing 960,374 shares valued at approximately $86.20 million.
• Merck reported earnings of $2.13 per share, which surpassed analysts' expectations of $2.03, though revenue was slightly below estimates at $15.81 billion.
• The company has declared a quarterly dividend of $0.81 per share, representing an annualized yield of 3.9% and a dividend payout ratio of 49.92%.

Strs Ohio acquired a new stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 960,374 shares of the company's stock, valued at approximately $86,203,000.

A number of other institutional investors have also recently added to or reduced their stakes in MRK. Ellsworth Advisors LLC increased its position in shares of Merck & Co., Inc. by 18.0% during the 1st quarter. Ellsworth Advisors LLC now owns 12,870 shares of the company's stock valued at $1,155,000 after purchasing an additional 1,964 shares during the period. Intrua Financial LLC raised its position in Merck & Co., Inc. by 36.4% in the first quarter. Intrua Financial LLC now owns 7,144 shares of the company's stock worth $641,000 after acquiring an additional 1,906 shares in the last quarter. Jacobi Capital Management LLC lifted its holdings in Merck & Co., Inc. by 4.4% in the 1st quarter. Jacobi Capital Management LLC now owns 64,511 shares of the company's stock valued at $5,790,000 after acquiring an additional 2,722 shares during the last quarter. Advisors Capital Management LLC boosted its position in shares of Merck & Co., Inc. by 11.7% during the 1st quarter. Advisors Capital Management LLC now owns 132,874 shares of the company's stock valued at $11,927,000 after purchasing an additional 13,867 shares in the last quarter. Finally, SWS Partners grew its stake in shares of Merck & Co., Inc. by 2.8% in the 1st quarter. SWS Partners now owns 20,169 shares of the company's stock worth $1,810,000 after purchasing an additional 545 shares during the last quarter. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Merck & Co., Inc. Stock Performance

Shares of NYSE MRK opened at $84.06 on Thursday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.42 and a quick ratio of 1.17. Merck & Co., Inc. has a one year low of $73.31 and a one year high of $119.38. The business's 50-day moving average price is $82.81 and its two-hundred day moving average price is $82.95. The company has a market capitalization of $209.96 billion, a P/E ratio of 12.95, a price-to-earnings-growth ratio of 0.87 and a beta of 0.37.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its quarterly earnings results on Tuesday, July 29th. The company reported $2.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.03 by $0.10. The business had revenue of $15.81 billion during the quarter, compared to analyst estimates of $15.92 billion. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. Analysts anticipate that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, October 7th. Stockholders of record on Monday, September 15th will be issued a dividend of $0.81 per share. The ex-dividend date is Monday, September 15th. This represents a $3.24 dividend on an annualized basis and a dividend yield of 3.9%. Merck & Co., Inc.'s dividend payout ratio (DPR) is currently 49.92%.

Wall Street Analysts Forecast Growth

MRK has been the subject of a number of research reports. Cantor Fitzgerald cut shares of Merck & Co., Inc. from an "overweight" rating to a "cautious" rating in a report on Tuesday, May 20th. Wells Fargo & Company decreased their price target on Merck & Co., Inc. from $97.00 to $90.00 and set an "equal weight" rating for the company in a research report on Wednesday, July 30th. Citigroup reaffirmed a "neutral" rating and set a $84.00 price objective (down from $115.00) on shares of Merck & Co., Inc. in a research note on Wednesday, May 14th. Finally, Morgan Stanley dropped their target price on shares of Merck & Co., Inc. from $99.00 to $98.00 and set an "equal weight" rating on the stock in a research report on Thursday, July 10th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of "Hold" and an average price target of $107.44.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.